MediciNova announced that the Phase 2b clinical trial evaluating MN-166 for the treatment of alcohol use disorder has completed enrollment. This clinical trial was funded by the National Institute on Alcohol Abuse and Alcoholism. The NIAAA R01 research funding was awarded to Principal Investigator Dr. Lara Ray, PhD, ABPP, at the University of California, Los Angeles’ Departments of Psychology, and Psychiatry and Biobehavioral Sciences Brain Research Institute. The clinical trial evaluated MN-166 as a potential treatment to decrease alcohol consumption in treatment-seeking individuals diagnosed with AUD. MediciNova provided drug supply and regulatory support for the clinical trial. Lara Ray, PhD, Principal Investigator of the study, commented, "We have completed enrollment and are conducting follow-up on the last of the participants. Recent studies of MN-166 (ibudilast) have shown it to be a safe and promising compound for the treatment of AUD and we are eager to begin the analysis."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on MNOV:
- MediciNova Announces Completion of Enrollment in the Phase 2b Clinical Trial of MN 166 (ibudilast) in Alcohol Use Disorder
- MediciNova Announces Completion of Enrollment in the Phase 2 Clinical Trial Evaluating MN-166 (ibudilast) for Treatment of Recurrent and Newly Diagnosed Glioblastoma
- MediciNova completes enrollment in Phase 2 trial of MN-166 in glioblastoma
- MediciNova receives Notice of Allowance for patent covering MN-001, MN-002
- MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Scleroderma and Systemic Sclerosis in Canada
